PLUS THERAPEUTICS, INC.

For the period ended Sep 30, 2025. Filed Oct 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 30, 2025

CNSY$0.57-11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2025	2024	2025	2024
Grant revenue	$1,397	$1,456	$3,846	$4,412
Operating expenses:
Research and development	2,436	2,858	5,438	8,394
General and administrative	3,443	2,397	7,964	6,813
Total operating expenses	5,879	5,255	13,402	15,207
Operating loss	(4,482)	(3,799)	(9,556)	(10,795)
Other income (expense):
Interest income	59	80	87	219
Interest expense	—	(61)	(548)	(122)
Financing expenses	—	—	(3,061)	(3,545)
Warrant issuance costs	—	(54)	(964)	(486)
Change in fair value of derivative instruments	—	960	(2,631)	5,654
Total other income (expense)	59	925	(7,117)	1,720
Net loss	$(4,423)	$(2,874)	$(16,673)	$(9,075)
Per share information
Net loss per share of common stock – basic	$(0.04)	$(0.37)	$(0.29)	$(1.46)
Weighted average number of shares of common stock outstanding – basic	107,428,969	7,855,763	57,845,406	6,232,123
Net loss per share of common stock – diluted	$(0.04)	$(0.37)	$(0.29)	$(1.67)
Weighted average number of shares of common stock outstanding – diluted	107,428,969	7,855,763	57,845,406	8,452,338

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.